LFWD vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LFWD exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is experiencing a collapse in top-line growth with revenue declining by 32.7% YoY, coupled with an unsustainable operating margin of -112.69%. Despite a low Price/Book ratio, the massive negative ROE (-146.12%) and consistent earnings misses (0/4 in the last year) suggest a failing business model. The extreme disconnect between the current price ($6.57) and the analyst target ($20.00) is not supported by any available fundamental data.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LFWD vs MRK: Head-to-Head Comparison
This page compares Lifeward Ltd. (LFWD) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.